Todd Fehniger, MD, PhD

Todd Fehniger, MD, PhD

Bone Marrow Transplant Specialist, Medical Oncologist

Primary Academic Title

Professor of Medicine, Division of Oncology, Sections of Stem Cell Biology and Bone Marrow Transplantation, Washington University School of Medicine

Clinical Expertise

Lymphoma, cellular therapy and bone marrow transplantation

Research Interest

The long-term goals of my laboratory are to better understand the molecular programs that regulate natural killer (NK) cell development and activation and translate basic NK cell biology into novel treatments for patients with cancer. My clinical interests are lymphoma, cellular therapy and hematopoietic stem-cell transplantation.

Education

  • 2000: PhD, immunology, Ohio State University, Columbus
  • 2002: MD, Ohio State University

Training

  • 2002 - 2004: Intern and resident, internal medicine, Washington University, St. Louis
  • 2004 - 2008: Fellow, hematology and oncology, Washington University

Board Certification

  • 2006: American Board of Internal Medicine, Internal Medicine
  • 2009: American Board of Internal Medicine, Medical Oncology

Selected Research Publications

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
  • Fehniger TA, Watkins MP, Ezenwajiaku N, [...] Bartlett NL
  • Haematologica 2024
T-BET and EOMES sustain mature human NK cell identity and antitumor function.
  • Wong P, Foltz JA, Chang L, [...] Fehniger TA
  • J Clin Invest 2023
Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction.
  • Selli ME, Landmann JH, Terekhova M, [...] Fehniger TA, [...] Singh N
  • Blood 2023
Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice.
  • Shrestha N, Chaturvedi P, Zhu X, [...] Fehniger TA, [...] Wong HC
  • Aging Cell 2023
Computational prediction of MHC anchor locations guides neoantigen identification and prioritization.
  • Xia H, McMichael J, Becker-Hapak M, [...] Fehniger TA, [...] Griffith M
  • Sci Immunol 2023
Allogeneic natural killer cell therapy.
  • Berrien-Elliott MM, Jacobs MT, Fehniger TA
  • Blood 2023
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
  • Berrien-Elliott MM, Becker-Hapak M, Cashen AF, [...] Fehniger TA
  • Blood 2022
Memory-like Differentiation Enhances NK Cell Responses to Melanoma.
  • Marin ND, Krasnick BA, Becker-Hapak M, [...] Fehniger TA
  • Clin Cancer Res 2021

Contact Information

  • Washington University Medical Campus

    4921 Parkview Place
    Saint Louis, MO 63110

Phone Numbers

Request an appointment